Profusa (PFSA) Company Report

Profusa, Inc. (PFSA) announced a one-for-seventy-five (1:75) reverse stock split of its common stock.
The reverse stock split will become effective at 12:01 a.m. Eastern Time on February 9, 2026, with post-split trading on The Nasdaq Global Market under the existing ticker symbol "PFSA" and a new CUSIP number 74319X 207.
As a result of the split, outstanding common shares will be reduced from approximately 92.4 million to approximately 1.2 million, while authorized shares will remain at 601 million.
Stockholders will receive a cash payment in lieu of any fractional shares.

2 days ago

Profusa, Inc. outlines path to revenue generation and provides financial projections

PFSA

Guidance Update

Product Launch

New Projects/Investments

Profusa, Inc. (PFSA) expects to launch its Lumee tissue oxygen monitoring in the EU in 2Q 2026, followed by U.S. entry in 1Q 2027.
The company projects potential revenue of $0.5 to $2 million in 2026, increasing to $9 to $13 million in 2027, and targeting $200 to $250 million by 2030.
Profusa's Lumee platform targets a $10.5 billion+ global addressable market for tissue oxygen monitoring and aims to reach over 500 million people with its continuous glucose monitoring technology.
Development has been supported by over $100 million in investment, including a $22 million PIPE and a $100 million Equity Line of Credit.

Oct 30, 2025, 11:40 AM

Profusa, Inc. Updates Investor Presentation with Revenue Projections and Product Launch Timelines

PFSA

Guidance Update

Product Launch

New Projects/Investments

Profusa, Inc. released an updated investor presentation on October 20, 2025, highlighting its strategy for "Pioneering real time biochemistry that drives AI - led, personalized healthcare technologies".
The company projects revenue from its Oxygen Platform to be between $0.5 million and $2 million in 2026, with total revenue from its Oxygen and Glucose platforms expected to reach $200 million to $250 million by 2030.
Profusa anticipates launching its Lumee tissue oxygen monitoring in Europe in 1Q2026E and in the US in 1H2027E, with revenue from glucose monitoring projected to commence in 2027.
Financially, Profusa has secured a $22 million PIPE and has access to a $100 million Equity Line of Credit, with $14.0 million in total cash availability as of October 20, 2025.

Oct 20, 2025, 9:51 PM

Profusa Invests Additional $1 Million in Digital Treasury Assets and Details Collateral Agreement

PFSA

New Projects/Investments

Debt Issuance

Profusa, Inc. announced on October 7, 2025, an additional $1 million investment in digital treasury assets, bringing its total to $2 million as part of its strategy to hedge against macroeconomic uncertainties.
This investment is linked to a financing arrangement with Ascent Partners Fund LLC, involving senior secured convertible promissory notes.
The Second Tranche of this financing, with a purchase price of $2,000,000, closed on September 30, 2025.
An Account Control Agreement, effective September 29, 2025, was established with Ascent, BitGo Prime LLC, and BitGo Trust Company, Inc. to govern the custody of Profusa's Bitcoin reserve, which is pledged as collateral for the financing.
Profusa is responsible for a collateral management fee of 3 basis points of the U.S. monthly digital assets held in the custodial account, payable to BitGo Prime LLC.

Oct 7, 2025, 10:13 PM

Profusa Amends Securities Purchase Agreement and Convertible Note Terms

PFSA

Debt Issuance

Convertible Preferred Issuance

Delisting/Listing Issues

Profusa, Inc. entered into Amendment No. 1 to its Securities Purchase Agreement and Senior Secured Convertible Promissory Note on August 25, 2025, restructuring its financing and modifying conversion terms.
The amendment to the Securities Purchase Agreement now provides for four tranches of Notes, with the First Tranche of $10,000,000 in aggregate principal amount already closed on July 11, 2025.
Subsequent tranches include a Second Tranche of $2,222,222 (purchase price $2,000,000), a Third Tranche of $5,555,556 (purchase price $5,000,000), and a Fourth Tranche of $4,444,444 (purchase price $4,000,000), each subject to specific conditions.
The amendment to the Senior Secured Convertible Promissory Note establishes a Conversion Price that is the lower of a specified amount or 95% of the lowest VWAP over the preceding ten trading days, with a Floor Price set at 20% of the Closing Sale Price on August 22, 2025.